Abstract. This study describes the identification of seven amino acid residues of the vascular cell adhesion molecule (VCAM-1) that influence binding to the ot4/31 receptor. Using recombinant murine VCAM-1-IgG, which is bound by both mouse (WEHI 231) and human (Ramos) lymphoid cells, two approaches demonstrated the crucial role of the first two NH2-terminal Ig-like domains in binding: (a) blocking monoclonal anti-mouse VCAM
T n~ vascular cell adhesion molecule-1 (VCAM-1) 1 plays a major role in the adhesion of leukocytes to inflamed microvascular endothelium (6, 27, 37, 45) , being one of a few molecules that are induced by proinflammatory cytokines such as IL-1, TNF-¢, or IFN-,y. It is involved with intercellular adhesion moleculeq and endothelial-leukocyte adhesion moleculeq in the transmigration and localization of lymphocytes, monocytes, eosinophils, and basophils (but not neutrophils) to sites of tissue inflammation (7, 19, 26, 44) . Its interaction with these types of leukocytes appears to be via very late antigen-4 (VLA-4, t~4/51), a/31 integrin molecule found on all four, but not on neutrophils (12) . It also has been shown to interact with ot4/37 (ot4/3P), the lymphocyte Peyer's patch homing receptor (8, 40) . VCAM-1 expression has been detected not only on cytokine-activated endothelium, but also on bone marrow stromal cells (22, 23, 41) , myoblasts (39) , lymphoid dendritic cells and tissue macrophages (38) , rheumatoid synovium (20, 35, 47) , cytokinestimulated neural cells (4) , parietal epithelial cells in Bowman's capsule, and renal tubular epithelium associated with nephritis (43, 52) . It has been detected at various sites of inflammation associated with cardiac and renal allograft transplant rejection (5, 14, 29) and with acute graft versus host disease of the large intestine (25) . Treatment of experimental animals with monoclonal antibodies to VCAM-1 has delayed murine cardiac allograft rejection (29, 30) . Antio~4 and/or anti-VCAM-1 monoclonal antibodies have been shown to block migration of lymphocytes, monocytes, and eosinophils into tissue, and to exhibit anti-inflammatory effects in animal models of experimental allergic encephalomyelitis, contact hypersensitivity reactions, and passive cutaneous anaphylaxis (1, 13, 18, 50, 53) .
Structurally, VCAM-1 has been described as a member of the immunoglobulin superfamily. It is expressed on cytokineactivated endothelium as either a 110,000-mol wt transmembrane glycoprotein with seven Ig-like extracellular domains, or as alternatively spliced six or eight Ig-like domain forms (9, 16, 27, 32, 33, 37) . The predominant form in the human, mouse, rat, and rabbit is reported to be the sevendomain form (9, 16, 32, 33) . More recently, VCAM-1 has been seen expressed as a truncated 40,000-mol wt phospha-tidyl inositol-linked form on endotoxin-treated lung and kidney tissues (24) .
There have been recent reports that molecules comprising only the NH2-terminal domains 1-3 were sufficient for both adhesion and costimulatory activation of T lymphocytes (10, 31) . Two studies reported that the first NI-Ix-terminal domain and the homologous domain 4 were involved in binding to 48) . In the work presented here, we investigate the binding of a panel of secreted recombinant DNAderived, murine VCAM-1 molecules to murine and human c~4B1 to elucidate the structure/function relationships for adhesion. We will show that a cluster of amino acids in domain 1 of VCAM-1 are crucial for binding to the c~4~1 receptor of mouse WEHI 231 and human Ramos cells.
Materials and Methods

Cloning and Expression of Murine VCAM-I
A mouse peripheral lymph node eDNA library was constructed using a eDNA library kit (lambda gtl0; Invitrogen, San Diego, CA) and poly(A) + RNA isolated from murine TNF-c~-stimulated mouse peripheral lymph nodes. The probe used to screen a library of ,~1 million lambda gtl0 bacteriophage was a random-primed (Boefiringer Mannheim Biochemicals, Indianapolis, IN) full-length eDNA encoding human VCAM-1 (gift of D. Dowbenko, Genentech Inc., South San Francisco, CA). Hybridizing clones were subcloned into pBluescript (Stratagene, La Jolla, CA) and sequenced using the Sequenase Version 2.0 kit (United States Biochemical Corp., Cleveland, OH). A full-length eDNA was identified and entirely sequenced. The sequence for our murine VCAM-1 was identical to that reported by Hession et al. (17) .
The eDNA for murine VCAM-1 was truncated to remove the nucleotides encoding both the transmembrane domain and the cytoplasmic tail (at amino acid residue N667) using the following primers:
The 2.2-kb EcoRI-Sall PCR product was subcloned into pRK5 and expressed in human 293 embryonic kidney cells as previously reported (2) . The resulting truncated murine VCAM-1 molecule was designated as MVdl-7. A 2.2-kb EcoRI-EcoRV PCR product was ligated to an EcoRV-SalI fragment encoding the hinge, CH2, and CH3 regions of murine IgG1. The resulting EcoRI-SalI fragment containing the murine VCAM-I-IgG chimera (designated MVIdl-7) was subcloned into a eucaryotic expression vector pRK5 and expressed in human 293 cells.
Purification of these proteins proceeded as follows: Scram-free conditioned medium from 293 cells expressing MVdl-7 was purified by affinity chromatography on rabbit antimurine MVdl-7-Sepharose (Pharmacia LKB Biotechnology Inc., Piscataway, NJ). MVIdl-7 was passed over protein A-Sepharose (Pharmacia, Uppsala, Sweden). Both types of molecules were eluted with 100 mM acetic acid, 500 mM sodium chloride, pH 3.0. The eluents were dripped into one-tenth volume of 1 M Tris (pH 7.5) to neutralize the samples. The samples were then dialyzed against phosphate-buffered saline, and concentrated using a pressurized stir cell (Amicon Corp., Danvers, MA.). The proteins were run on 7% SDS-PAGE to assess purity. The MVdl-7 was a monomer of 110 kD under both nonreducing and reducing conditions. The MVIdl-7 was a dimer of 230,000 mol wt under nonreducing conditions and a monomer of 115,000 tool wt under reducing conditions.
Truncated Variants of Murine VCAM-I-IgG Chimera
MVIdl-7 is composed of seven Ig-like domains. Experiments were carried out with domain truncation variants. Each domain of MVIdl-7 was sequentially truncated, starting at the COOH terminus (domain 7), to evaluate the binding function of each truncation variant. Domains in the murine molecule were defined as regions homologous to the human molecule according to Osborn et al. (27) : domain 1 comprised amino acid residues F1 to I84; domain 2, H85 to L193; domain 3, Q194 to E286; domain 4, K287 to $378; domain 5, F379 to Y482; domain 6, V483 to V574; and domain 7, $575 to H666. Primers were synthesized to truncate the full-length eDNA by PCR (Perkin-Elmer Cetus Instruments, Norwalk, CT) before amino acid positions H85, Q194, K287, F379, V483, and $575. Each primer introduced restriction endonuclease sites as well as a stop codon to facilitate subcloning and expression. To aid in the purification of the truncated VCAMs, further constructs were made in which the cDNA encoding the hinge, CH2, and CH3 of murine IgG1 were ligated to each of the truncated cDNAs to generate Ig chimeras. They were designated as MVIdl, MVIdl-2, MVIdl-3, MVIdl-4, MVIdl-5, and MVIdl-6, respectively, with the wild type (WT) as MVIdl-7.
Site-directed Mutagenesis of VCAM-I-IgG Chimera
Mutations were introduced into the cDNAs encoding MVIdl-4 and MVIdl-7 by the method of Kunkel et al. (21) (Muta-Gene Phagmid In Vitro Mutagenesis Kit; Bio-Rad Laboratories, Richmond, CA) according to the manufacturer's instructions. Plasmids positive for the introduced mutations were confirmed by sequencing and expressed transiently in 293 cells. The concentration of each mutant in serum-free conditioned medium was quantified by ELISA using a goat anti-mouse IgG1 antibody as previously described (49) . Mutation sites were defined using the following nomenclature: IMOA describes aspartic acid mutated to an alanine at position 40.
Antibodies
HP2/1 (rat anti-human a4 chain) was purchased from Amac, Inc. (Westbrook, ME). It has been previously described and reported to bind human a4 and block lymphocyte binding to haman VCAM-1 and fibronectin (36, 42) . PS/2 (rat anti-mouse a4 chain-specific antibody) was obtained from the American Type Culture Collection (Rockville, MD). It has been previously reported to recognize the a4 chain of murine VLA-4 (22) . Rabbit anti-mouse VCAM-1 (anti-mVCAM-1) antiserum was prepared by immunization of rabbits with recombinant derived MVIdl-7 in Freund's adjuvant. It was purified on protein A and immunoaffinity depleted of anti-mouse IgG activity on Sepharose-conjugated mouse IgG (Pharmacia LKB Biotechnoiogy Inc.). The preparation was 0.28 mg/ml with and endpoint titer of >1:25,600 for anti-MVdl-7 and 1:158 for anti-mouse IgG by ELISA analysis. A concentration of 10 #g/mi was used in blocking experiments. It specifically blocked adhesion of WEHI 231 to 24-h TNF-c~-stimulated mouse hemangioendothelioma cells, but had no effect on blocking Ramos cells binding to TNF-a-stimnlated human umbilical cord vein endothelial cells (Cell Systems Corp., Kirkland, WA).
Armenian hamsters were immunized intraperitoneally with 5 #g of recombinant MVIdl-7-emulsified in monophosphoryl lipid A/trehalose dimycolate adjuvant (Ribi ImmunoChem Research, Inc., Hamilton, MT). 3 d later, the spleens from the immunized animals were fused with P3x63Ag801 myeloma cells using polyethylene glycol. Positive antimVCAM-1 hybridomas were screened by ELISA for binding to soluble MVdl-7. Seven monoclonal antibodies were selected and characterized. These were designated 5. The hamster anti-mVCAM-I antibodies were used to assess structural alterations in the MVIdl-4 and MVIdl-7 site-directed mutants. The 293 cell transfectant supernatants (100 #1) from the mutants were added to coats of 0.2 #g/ml goat anti-mouse IgG (Cbemicon International Inc., Tecmecula, CA) on microtest wells (NUNC-Immuno Plate, MaxiSorp; Alameda Chem. & Sci., Inc., Oakland, CA) that had been blocked with 10 mg/ml of BSA in phosphate-buffered saline for 2 h at room temperature. An equivalent amount of mutant and MVIdl-4 or MVIdl-7 (WT) protein were incubated for 1 h at room temperature. 100 #1 of each monoclonal hamster anti-mVCAM-1 antibody solution was added, and the microtest wells were again incubated for 1 h at room temperature. The bound hamster antibodies were detected by a 1-h incubation with goat anti-hamster IgG labeled with alkaline phosphatase at 1:2,000 dilution (Caltag Laboratories, South San Francisco, CA). The enzyme activity was detected with 1 mg/ml ofp-nitrophenyl phosphate, disodium (Sigma Chemical Co., St. Louis, MO), in 50 mM carbonate, 10 mM MgCI2 for 30 rain at room temperature. The optical density at 405 nm was recorded on a microplate reader (Molecular Devices Corp., Menlo Park, CA).
Two blocking rat anti-mVCAM-1 antibodies were used for binding studies and for the assessment of changes to gross structure. The M/K-2.7 was obtained from the American Type Culture Collection. It has been described as a blocking antibody for the binding of human lymphoma cells to mouse endothelial ceils (23) . MVCAM.A429 was obtained from PharMingen.
Cell Adhesion Assay
Recombinant MVdl-7 and MVIdl-7 were precoated onto separate microtest wells (NUNC-Immuno Plate, MaxiSorp) at 1 ~g in 100/zl/well for 1 h at room temperature. The wells were quenched with RPMI 1640 containing 5 mg/mi BSA. The test cells were labeled with 2',7'-bis-(2-carboxyethyl)-5(and-6)-carboxyfluorescein, acetoxymethyl ester (BCECF) from Molecular Probes (Eugene, OR) for 30 rain at 37°C according to the method of Gimbrone et al. (15) . The labeled cells were suspended at 4 x 106 cells/mi in RPMI 1640 containing 5 mg/mi BSA. Test cells were incubated with immobilized MVdl-7, or MVIdl-7, at 37"C for 15 min. The nonadherent cells were removed by centrifugation of the sealed microtest plate in the inverted position at 200 g for 5 min. The supernatant was aspirated. The bound ceils were solubilized with 0.1% SDS in 50 mM Tris/HCl, pH 8.5. The proportion of adherent ceils was determined for each well by measuring the amount of released fluorochrome from lysed cells on an analyzer (Fluorescence Concentration Analyzer; Pandex, Mnndelein, IL) set at 485-nm excitation and 535-nm emission wavelengths. Adherence was also performed on microwells precoated with human fibronectin (Sigma Chemical Co.).
For the test of MVIdl-4 and MVIdl-7 site-directed mutants in the adhesion assay, serum-free culture suporuatants from 293 cell transfectants were serially added to microwells that had been coated with 200 w/well goat anti-mouse IgG1 (Caltag Laboratories) and quenched with 5 mg/ml BSA. Supernatants were incubated for 2 h at room temperature. For the assessment of the amount of each mutant protein captured on the microwells, an alkaline phosphatase-labeled goat anti-mouse IgG1 (Caltag Laboratories) at hl,000 dilution was added, and wells were incubated for 1 h at room temperature. The enzyme activity was detected with p-nitrophenyl phosphate disodium, taking optical density readings at 405 nm. The sensitivity of this capture assay was such that protein concentration determinations and cell binding analysis of mutants could be made within the concentration range of 20-150 w/ml. The cell adhesion assay described above was repeated with the following variation for both MVIdl-4 and MVIdl-7. For the assessment of Ramos cell binding to mutant MVI, BCECF-labeled cells were added as above. FOr WEHI 231 cell binding, a rat anti-mouse Fe3,RII antibody (PharMingen) at 2 t~g/10 ~ cells was added to block binding through the Fc receptor (46) . To block the binding of WEH1231 cells through the cell-surface IgG to the goat anti-mouse IgGl precoat, 2 t~g/ml of mouse IgG1 (Calbiochem, San Diego, CA) was added to the assay medium.
Model of Murine VCAM-1 Domain 1
A model of MVdl was based on the crystal structure of a human IgG CH1 domain (11) . Alignment of the MVdl sequence with CH1 ( Fig. 1 ) was performed manually using C23, C71, W35, $54, and the requirement for hydrophobic residues at buried positions to guide the alignment. In human CH1, the W35 sidechain forms a hydrogen bond with the $54 sidechain; this was retained in the MVdl model. Insertions and deletions in MVdl relative to human CH1 occur in the loops connecting the/~ strands. In addition, /~ strands D and E are shorter in MVdl (Fig. 1) .
CHI was transformed into MVdl in two steps. First, all residues except those involving insertions or deletions were changed to the MVdl sequence using the INSIGHT-II program (Biosym Technologies, San Diego, CA). Where possible, conformations of MVdl sidechains were kept similar to those of CHI; otherwise, they were based on rotamer libraries (34), packing, and hydrogen bonding considerations. Second, loop structures containing the MVdl insertions or deletions were gleaned from searches of the Protein Data Bank (3) crystal structures using the INSIGHT-I/ program. Several loop conformations were possible for each new loop, and in each case, the choice was based on the nature of the MVdl amino acids. The loop connecting/~ strands C and D (loop CD) is relatively large (10 residues) and several loop conformations were evaluated.
The MVdl model was subjected to energy minimization using the DIS-COVER program (Biosym Technologies). The all-atom AMBER foreefield (51) was used for all calculations, using a 14-/~ cutoff for nonbonded interactions and a linear dielectric (¢ = 4.0*0. Before minimization, hydrogen atoms were added to the structure using INSIGHT-H, and positions of hydrogens on serine, threonine, and tyrosine sidechains were checked visually for proper alignment in hydrogen bonds, if present. Energy minimi- zation was performed in three stages. In stage one, 500 cycles of steepestdescents minimization were used. 46 hydrogen bond constraints (50 kcal/mol) were also invoked: 37 mainchain-mainchain, 8 mainchainsidechain, and 1 sidechain-sidechain hydrogen bonds. This allowed new loop structures and all sidechains to move while preserving the integrity of the CHI protein fold. In stage two (1,000 cycles), conjugate-gradient minimization was used. In stage three (5,690 cycles), the hydrogen bond constraints were released, and the minimization continued until the maximum derivative was <0.01 kcal/mol-/~.
Results
Cell Binding to Immobilized Recombinant Murine VCAM-1 (MVdl-7) and Murine VCAM-I-IgG (MVIdl-7)
Two secreted, soluble, and recombinant forms of murine VCAM-1 exhibited binding specificity to ot4/31-positive lymphoid cells. BCECF-labeled murine WEHI 231 and human Ramos cells bound to both MVdl-7 and MVIdl-7 above the basal level binding that they exhibited with BSA (Fig. 2, A and C). The binding of the murine and human cells was inhibited by PS/2 (anti-murine ol4 subunit antibody) and HP2/1 (anti-human oL4), respectively, but not by a rat IgG2b isotype control antibody (Fig. 2, B and D) . A rabbit antimurine VCAM-I antiserum also inhibited binding. This binding These data showed that the recombinant soluble molecules MVdl-7 and MVIdl-7 were functionally active, similar in their interaction with the homologous mouse VLA-4 receptor, and cross-reactive with VLA-4 from several other different animal species, including humans.
Binding of Cells and Anti-VCAM-1 Monoclonal Antibodies to Truncated Variants of MVIdl-7
The first two NH2-terminal Ig-like domains on murine VCAM-1 were both necessary and sufficient for binding to murine WEH1231 and human Ramos cells. Domain deletion mutants, expressed as chimeric IgG molecules in serum-free conditioned media, were captured on separate microwells precoated with goat anti-mouse IgG antibody and presented to cells at 0.23 nM. This concentration had previously been determined to be saturating for all variants by an immunoassay under the antibody capturing condition. As illustrated in Fig. 3, A The binding by Ramos cells to the MVI variants could be inhibited totally by monoclonal hamster anti-mVCAM-1 (clone 59.17.19), but not by normal hamster IgG (Fig. 3 C) . Inhibition was also observed for another monoclonal hamster anti-mVCAM-1 (clone 59.9.4) and two commercially available blocking rat anti-mVCAM-1 antibodies tested, M/K-2.7 (23) In corroboration, blocking monoclonal antibodies (59.9.4, 59.17.19, M/K-2.7, and MVCAM.A429) were observed to bind to truncated routine VCAM-I-IgG molecules bearing, at minimum, the first two NH2-terminal Ig-like domains, MVIdl-2 to MVIdl-7 (Table I) . Nonblocking monoclonal antibodies bound to MVIdl-3 through MVIdl-7, but not to MVIcI1-2. None of the antibodies tested bound to MVIdl. These results support the hypothesis that the structures Fig. 4, B and D, respectively. The lack of binding by Ramos cells to the D40K mutant was identical to that observed for D40A (data not shown). Based on a computergenerated model of domain 1 (Fig. 5) , the D40 residue is associated with a/~ turn between ~ strands C and D. Mutation of this hydrophilic residue should not greatly perturb the Figure 5 . Computer-generated model of the first domain of murine VCAM-1. /3 strands are shown as beige-colored ribbons; ~-helix (loop EF and part of loop AB) is in purple, Relevant sidechains tested for their effect on binding are colored as follows: blue, no effect; green, partial reduction; yellow, complete reduction; and red, protein not expressed. Residue numbers are provided for sidechains that had a complete or partial reduction in binding. This figure was drawn using MIDAS (University of California, San Francisco).
Specific Amino Acid Residues on Domain I of MVIdl-4 and MVIdl-7 Are Required for Cell Binding
A series of soluble MVIdl-4 mutants with L-alanine or L-lysine substitutions in domain 1 residues was expressed in 293 cells to test whether the first domain alone was sufficient
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structure of the molecule. For comparative purposes, the K10 residue is located within a loop connecting two/3 strands A and B. Mutation to K10A did not disrupt the binding by WEH1231 or Ramos ceils (Fig. 4 J) , nor did it induce gross structural changes (Table M) .
This stands in contrast to the $54A mutation, which did result in reduction of cell adherence and of the binding of nonblocking and blocking antibodies (Table M) . Binding by blocking antibodies was reduced by 83-93 %, while that of nonblocking antibodies was reduced by 24-53%. Based upon the computer model, $54A is likely buried within/3 strand E and forms a hydrogen bond with W35 (Figs. 1 and 5) and thus is essential for the structural integrity of the molecule.
Alanine substitutions at R36, K46, T72, and E81 also resulted in reduced binding of Ramos cells (Table 1I and  Figures 4 , A, C, L and F,, respectively). All four of these residues seemed to be structurally important. R36 is next to W35, which is hydrogen bonded to $54. The importance of this bond is also borne out by mutation of $34, which simi- +  103  115  96  H67A  -0  0  0  L70A  -0  0  0  T72A  +  72  60  80  K79A  +  101  95  96  E81A  +  95  98  96  R82A  +  107  96  97  H85A  +  83  69  83   100  100  100  100  100  100  0  0  0  0  0  0   104  104  68  61  123  105  103  109  100  104  97  103  92  94  89  84  108  109  0  0  0  0  ND  ND  60  65  62  70  51  41  76  81  76  73  71  42  60  59  63  66  50 12  17  51  58  53  45  53  53  77  82  80  82  86  87  97  104  97  97  101  110  61  61  39  36  80  77  106  106  97  91  105  107  0  0  0  0  ND  ND  0  0  0  0  ND  ND  69  70  77  87  73  71  94  91  104  105  88  101  92  97  95  86  91  73  103  91  99  106  103  106  66  78  62  59  85  64 larly disrupts antibody binding, but not cell adherence. The R36A mutation had a profound effect on the binding of the blocking anti-VCAM-1 antibody MVCAM.A429. K46 is predicted to be within B strand D and partially buried. E81 is predicted to be within B strand G adjacent to R82, which is partially buried. T72 is on B strand F positioned between two buried residues C71 and A73, and might therefore be expected to reduce cell binding. Of particular interest is the finding that the degree of reduction in cell binding to the P,36, K46, T72, and E81 mutants was highly dependent on the concentration at which they were precoated on the microwells. Higher concentrations resulted in better binding, while lower concentrations resulted in poorer binding, as compared to equivalent concentrations of the wild type molecule. These data suggest that while the mutations could disrupt cell adhesive function, binding could be augmented by increasing the avidity of the interaction or the number of molecules interacting.
In general, the mutations that affected Ramos cell binding also affected the bindingto WEHI 231 cells. However, three mutants, K46A, N65A, and ES1A, exhibited reduced binding by Ramos cells while exhibiting little or no effect on WEHI 231 cell binding. Representations of N65A and E81A are shown in Fig. 4 , G and H. The N65A mutation completely reduced the binding of Ramos cells, while K46A and E81A only partially reduced binding. These results raise the possibility that there may be species differences in the recognition residues on MVIdl-4.
Alanlne substitutions at E8, K10, D17, T37, N44, R48, E50, T57, E64, E66, I(79, R82, and H85 did not alter binding by either Ramos or WEH1231 cells (Table ll) . There was no yield for the three mutations, E29A, H67A, and LTOA.
To further test whether a mutant at D40 in the MVIdl-7 molecule could also exhibit reduction in binding, a panel of mutants comprised of mutations D40A, D40E, D40K, and D40N were prepared: The mutants D40A, D40K, and D40N, tested at comparable molar concentrations to wild type MVIdl-7, reduced binding to background levels. The D40E mutation did not affect binding (Fig. 6) . The effect of mutation on IM0 was not unique to Ramos or WEH1231 cell binding. The human Jurkat T cell line binding to D4OA, D40K, and D40N MVIdl-7 mutant molecules was also completely inhibited (data not shown). These data are consistent with the idea that a change of a single amino acid residue, I)40 in domain 1 of the MVIdl-7 molecule, to a residue with either an aliphatic, basic, or amide sidechain is sufficient to completely abrogate its binding by a4 positive cells. An acidic sidechain composed of D40 or E40 was sufficient for binding.
Mutation of MVIdl-4 at positions D317A, R324A, Q326A, 
Specific Amino Acid Residues on Domain 1 of MVIdl-4 Are Required for the Binding of Neutralizing Hamster and Rat Anti-mouse VCAM-1 Monoclonal Antibodies
An analysis of the binding of a panel of adhesion-blocking and nonblocking hamster anti-VCAM-1 monoclonal antibodies was carried out to test whether the same amino acid substitutions that perturb cell adherence can result also in altering antibody binding or whether specific mutations induced gross structural perturbations in the molecule. Comparative data on the antibodies binding to mutants, relative to wild type are summarized in The mutation R36A reduced the binding of both blocking and nonblocking antibodies to a range of 73-81% of wildtype binding (average of 78%). In the experiments shown above, this mutation also resulted in reduced binding by both WEHI 231 and Ramos in a mutant dose dependent manner (Fig. 4) . The results suggest that this mutation may induce a subtle change in the conformation of the molecule, thereby impacting both antibody binding and adhesion.
The D40 residue was observed to be key to cell adherence. Anti-VCAM-1 antibody-binding data suggested that the D40A and D40K mutations did not result in gross structural perturbations (Table HI) . Only the binding of one blocking anti-VCAM-1 antibody (MVCAM.A429) was completely abrogated by the D40A and D40K mutations. The inference is that D40 is one residue crucial for cell adherence and binding by the blocking anti-VCAM-1 monoclonal antibody MVCAM.A429.
Both blocking and nonblocking antibodies showed reduced binding to mutants $54A and N65A as compared to wild type. $54A profoundly reduced the binding of blocking antibodies to 8 + 1% (SD) of wild type and the binding of nonblocking antibodies to 59 5: 11% of wild type. The $54A mutation also inhibited the adherence of both WEH1231 and Ramos. Similarly, the N65A mutant reduced blocking antibodies to 38 + 2% and nonblocking antibodies to 63 + 3%. Both of these mutations seem to more profoundly reduce blocking antibody binding than nonblocking antibody binding, thus suggesting that these residues influence the structural integrity of the molecule, but also contribute significantly to cell adhesive function.
In summary, alanine substitution of three residues (R36, $54, and N65) can partially affect the gross structure of mVCAM-1, as exemplified by their perturbation of anti-VCAM-1 antibody binding. These data are consistent with their effect on cell adhesion. Alanine substitution at E81 affected the binding of blocking antibody MVCAM.A429 only, with alteration at E81 causing reduction in binding by Ramos cells. Two residues, E8 and D17, seem to be associated with the binding of the two blocking anti-VCAM-1 antibodies, while having no direct influence on cell adhesion. D40A, the mutation with the most profound effect on cell adhesion, produced a measureable effect on the binding of only one blocking antibody, MVCAM.A429.
Discussion
We have shown that recombinant soluble mVCAM-1 molecules, secreted by human 293 cells either as a truncated molecule without the transmembrane and cytoplasmic tail domains, or as an IgG fusion molecule, exhibited ceU adhesive functions similar to those previously reported for cell mem-brane expressed forms of human VCAM-1. The binding was through the lymphocyte t~4/31 receptor. Both murine WEHI 231 and human Ramos cells binding to immobilized MVdl-7 or MVIdl-7 could be inhibited by antibodies to either a4 or VCAM-1.
The secreted MVIdl-7 molecule could be truncated to a smaller molecular form, composed of the first two NH2-terminal domains, that retained cell adhesive function comparable to that of MVIdl-7. Pepinsky et al. (31) reported that a soluble truncated form of human VCAM-1 derived from COS ceils and composed of the first two domains was bound by Ramos cells. However, the binding was not inhibited by anti-VCAM-1 antibody 4B9. In our investigation, the binding of WEHI 231 and Ramos cells to MVIdl-2 was totally inhibited by monoclonal hamster anti-mVCAM-1 antibodies 59.9.4 and 59.17.19. This minor difference may be explained by our use of a different monoclonal anti-VCAM-1 antibody or by the study of VCAM-1 derived from murine as opposed to human origin.
By alanine substitution of acidic and basic charged amino acid residues in the first domain, the D40 residue was found to strongly inhibit binding by both WEHI 231 and Ramos cells. A requirement for an acidic sidechain at amino acid residue 40 was evident with the D40E mutation showing no impact on cell binding, while D40A, D40K, and D40N inhibited binding. Alteration of the D40 residue in both the MVIdl-4 and the MVIdl-7 version of the soluble mVCAM-1 molecule led to complete loss of cell binding. Experimentally, the loss of adhesive function was not accompanied by global molecular structural perturbations, as tested by the binding of blocking or nonblocking hamster VCAM-1 antibodies. The location of D40 on a hydrophilic loop between /3 strand C and D of the VCAM-1 molecule suggests that this residue might interact directly with ot4/31 receptors. Its location is a region corresponding to the second complementarity determining region of immunoglobulins.
In our investigation, the D40A mutation alone in domain 1 of MVIdl-7 completely inhibited cell adhesiveness. Arguably, the first domain may make the greatest contribution to binding by our recombinant soluble VCAM-1 molecule. In our hands, mutation of MVIdl-4 at positions D317A, R324A, Q326A, D328A, R336A, E338A, and K341A did not result in reduced binding by Ramos or WEH1231 cells, suggesting that domain 4 is not required for adhesive function. This would appear to be in conflict with the report by Osborn et al. (27) , who showed that the fourth domain may have cell adhesive function. These investigators observed that a COS cell expressing the alternatively spliced six Ig-like domain form of human VCAM-1 was bound by Ramos cells. However, in their VCAM-1 molecule, the first domain was swapped for the fourth domain. Their results and ours are therefore complementary.
A second mutation involving $54A also reduced binding, probably by disrupting the hydrogen bonding that normally occurs between $54 and W35, as predicted by the computer model illustrated in Fig. 6 . The $54A mutation inhibited both blocking and nonblocking anti-VCAM-1 antibody binding with the effect being greater on blocking antibodies. The results suggest that the mutation most likely changed the local conformational structure of the molecule. If so, it follows that $54 would influence both cell adhesion and antibody binding.
There were two distinct patterns seen in the loss of cell binding to the mutants. The mutations D40A, $54A, and N65A abrogated cell adherence at all concentrations of mutants tested, whereas the R36A, K46A, and ES1A mutations exhibited cell binding at higher precoat concentrations, but not at lower mutant precoat concentrations. A possible explanation for the former observation is that the mutations D40 and $54 sufficiently reduced the affinity of the interaction so that increasing the mutant precoat concentrations did not lead to an increase in the avidity of the interaction. On the other hand, the R36A mutant had a lower affinity interaction that was overcome by increasing the precoat concentrations. These results strongly support the hypothesis that the D40 and $54 residues are crucial for maintaining adhesive function. These residues are conserved in the mouse, rat, and human VCAM-1 molecules.
The R36 and D40 residues are adjacent to four other altered residues that exhibited an influence on cell adhesion, mutations K46A, N65A, T72A, and E81A. The K46A, N65A, and E81A mutations inhibited partially or completely the binding by Ramos cells, while displaying no modification of the binding by WEH1231 cells. Possible explanations are (a) that homologous interactions between mouse cell and mouse protein may be of higher affinity than the heterologous ones between human cell and mouse protein; or (b) that the structures on MVIdl-4 involved in the binding to Ramos cells may be slightly different from those for binding to WEHI 231. Interestingly, these three residues are adjacent conformationally to R36 and D40. All are clustered within the same region of the molecule and are conserved among mouse, rat and human VCAM-1 sequences, suggesting their importance for cell adhesive function.
Only two residues were observed to block antibody association without contributing to cell adhesion. Alanine substitution at two residues, E8 and D17, were able to inhibit blocking antibody binding, but induced no effect on the binding by Ramos or WEHI 231 cells. Based on the computer model, these two residues are both located in the loop between/3 strand A and B (shown at the right hand bottom corner of Fig. 5 ). These residues are not in close proximity to the residues influencing cell adhesion.
Of the residues that did not affect binding either to Ramos or WEHI 231 cells, those at positions K10, R48, E64, and R82 differ in sequence between human, rat, and murine VCAM-1. This suggests that these positions are not involved in species specific interaction even though R48, E64, and R82 are adjacent to residues that did affect binding.
In summary, by site-directed mutagenesis of a secreted soluble recombinant murine VCAM-1 molecule, we have identified amino acid residues that influence both cell adhesion and binding by blocking monoclonal anti-VCAM-1 antibodies. In particular, the D40A mutation resulted in complete inhibition of both cell adhesive function and binding by blocking antibody MVCAM.A429 without inducing any other structural perturbation. The residues R36, 1340, K46, N65, T72, and ES1 are all conformationally close to one another on a hydrophilic region on the NH2-terminal domain 1. Although these residues are all located in domain 1, it is evident that there is a structural requirement for domains 1 and 2 to be intact so that cell binding can take place. The distribution of these residues on the same face of the molecule would suggest that the structure on VCAM-1 crucial for adherence to VLA-4 is probably conformationaUy dependent.
